[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,104
  • Shares Outstanding, K 12,810
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,860 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.20
  • Most Recent Earnings $-1.20 on 11/13/25
  • Next Earnings Date 05/21/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 251.33%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 957.60% on 07/01/25
  • IV Low 0.00% on 04/27/26
  • Expected Move (DTE 0) 0.0340 (1.18%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 24,187
  • Open Int (30-Day) 81,177
  • Expected Range 2.8460 to 2.9140

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 2
  • High Estimate $-0.29
  • Low Estimate $-1.20
  • Prior Year $-2.60
  • Growth Rate Est. (year over year) +71.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6572 +27.89%
on 03/31/26
1.0000 -15.95%
on 04/22/26
+0.1805 (+27.35%)
since 03/30/26
3-Month
0.5900 +42.46%
on 03/30/26
6.1400 -86.31%
on 02/09/26
-5.0075 (-85.63%)
since 01/30/26
52-Week
0.5900 +42.46%
on 03/30/26
23.2000 -96.38%
on 05/27/25
-16.9595 (-95.28%)
since 04/30/25

Most Recent Stories

More News
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company...

RVPH : 0.8409 (-2.99%)
Reviva Announces Letter to Shareholders

CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company...

RVPH : 0.8409 (-2.99%)
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package...

RVPH : 0.8409 (-2.99%)
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.8409 (-2.99%)
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.8409 (-2.99%)
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.8409 (-2.99%)
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine...

RVPH : 0.8409 (-2.99%)
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies...

RVPH : 0.8409 (-2.99%)
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the...

RVPH : 0.8409 (-2.99%)
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 –  – Potential NDA submission for schizophrenia indication targeted for Q2 2026...

RVPH : 0.8409 (-2.99%)

Business Summary

Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment...

See More

Key Turning Points

3rd Resistance Point 0.9735
2nd Resistance Point 0.9343
1st Resistance Point 0.9005
Last Price 0.8409
1st Support Level 0.8275
2nd Support Level 0.7883
3rd Support Level 0.7545

See More

52-Week High 23.2000
Fibonacci 61.8% 14.5630
Fibonacci 50% 11.8950
Fibonacci 38.2% 9.2270
Last Price 0.8409
52-Week Low 0.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.